In September, Numinus acquired Toronto Centre of Neurology, to expand the company’s footprint of ketamine clinics across Canada.
CEO Payton Nyquvest was a former director at Mackie Research Capital, and has raised over C$100 million for private and public companies – facilitating numerous IPOs. He spoke to PSYCH on Numinus’s expansion strategy and plans for the US.
Read More
At Prime Minister’s Questions, Johnson said he would respond to MP Crispin Blunt’s calls to legalise psilocybin ‘as soon as possible’.
Read More
To support increased research, the quotas for LSD and MDMA production would rise from 50g and 40g, to 500g and 3,200g respectively.
Read MoreEmotional Intelligence Ventures attracts US$20m in Regulation A raise.
Awakn receives Care Quality Commission approval to start UK ketamine treatments.
COMPASS Pathways files US patent for crystalline psilocybin.
PharmaTher receives orphan drug designation from FDA.
Cybin announces completion of pre-clinical trials.
Field Trip opens three new clinics across North America.
There are now 50 psychedelics companies listed in the US.
Nova Mentis and Mycrodose to co-develop drug delivery system.
Levitee Labs partners with Adracare for technology services.
Emyria partners with Eurofins for MDMA-analogue screening programme.
The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.
Key findings:
Johns Hopkins receives a federal research grant to study psilocybin.
Bank of America closes the account of DEA-registered psychedelics researcher.
Why ketamine-assisted therapy has gone mainstream.
Could a psychedelic ego death bring you back to life?
Oakland looks to expand decriminalisation to allow community-based sales.
The obstacles to decriminalising psychedelic drugs are political, not legal.